These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 17323187

  • 1. Pharmacological profile of ramosetron, a novel therapeutic agent for IBS.
    Hirata T, Funatsu T, Keto Y, Nakata M, Sasamata M.
    Inflammopharmacology; 2007 Feb; 15(1):5-9. PubMed ID: 17323187
    [Abstract] [Full Text] [Related]

  • 2. Effect of ramosetron on conditioned emotional stress-induced colonic dysfunction as a model of irritable bowel syndrome in rats.
    Funatsu T, Takeuchi A, Hirata T, Keto Y, Akuzawa S, Sasamata M.
    Eur J Pharmacol; 2007 Nov 14; 573(1-3):190-5. PubMed ID: 17658508
    [Abstract] [Full Text] [Related]

  • 3. Effects of serotonin 5-HT(3) receptor antagonists on CRF-induced abnormal colonic water transport and defecation in rats.
    Hirata T, Keto Y, Nakata M, Takeuchi A, Funatsu T, Akuzawa S, Sasamata M, Miyata K.
    Eur J Pharmacol; 2008 Jun 10; 587(1-3):281-4. PubMed ID: 18456254
    [Abstract] [Full Text] [Related]

  • 4. Effects of serotonin 5-HT3 receptor antagonists on stress-induced colonic hyperalgesia and diarrhoea in rats: a comparative study with opioid receptor agonists, a muscarinic receptor antagonist and a synthetic polymer.
    Hirata T, Keto Y, Nakata M, Takeuchi A, Funatsu T, Akuzawa S, Sasamata M, Miyata K.
    Neurogastroenterol Motil; 2008 May 10; 20(5):557-65. PubMed ID: 18221252
    [Abstract] [Full Text] [Related]

  • 5. Inhibitory effects of ramosetron, a potent and selective 5-HT3-receptor antagonist, on conditioned fear stress-induced abnormal defecation and normal defecation in rats: comparative studies with antidiarrheal and spasmolytic agents.
    Hirata T, Funatsu T, Keto Y, Akuzawa S, Sasamata M, Miyata K.
    J Pharmacol Sci; 2008 Feb 10; 106(2):264-70. PubMed ID: 18296863
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of the pharmacological profile of ramosetron, a novel therapeutic agent for irritable bowel syndrome.
    Hirata T, Keto Y, Funatsu T, Akuzawa S, Sasamata M.
    J Pharmacol Sci; 2007 Jul 10; 104(3):263-73. PubMed ID: 17652911
    [Abstract] [Full Text] [Related]

  • 7. Inhibitory effect of ramosetron on corticotropin releasing factor- and soybean oil-induced delays in gastric emptying in rats.
    Hirata T, Keto Y, Yamano M, Yokoyama T, Sengoku T, Seki N.
    J Gastroenterol Hepatol; 2012 Sep 10; 27(9):1505-11. PubMed ID: 22554268
    [Abstract] [Full Text] [Related]

  • 8. Pharmacological properties of 3-amino-5,6,7,8-tetrahydro-2-[4-[4-(quinolin-2-yl)piperazin-1-yl]butyl]quinazolin-4(3H)-one (TZB-30878), a novel therapeutic agent for diarrhea-predominant irritable bowel syndrome (IBS) and its effects on an experimental IBS model.
    Tamaoki S, Yamauchi Y, Nakano Y, Sakano S, Asagarasu A, Sato M.
    J Pharmacol Exp Ther; 2007 Sep 10; 322(3):1315-23. PubMed ID: 17540858
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine.
    Lee KJ, Kim NY, Kwon JK, Huh KC, Lee OY, Lee JS, Choi SC, Sohn CI, Myung SJ, Park HJ, Choi MK, Bak YT, Rhee PL.
    Neurogastroenterol Motil; 2011 Dec 10; 23(12):1098-104. PubMed ID: 21920001
    [Abstract] [Full Text] [Related]

  • 10. Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea.
    Fukudo S, Ida M, Akiho H, Nakashima Y, Matsueda K.
    Clin Gastroenterol Hepatol; 2014 Jun 10; 12(6):953-9.e4. PubMed ID: 24315882
    [Abstract] [Full Text] [Related]

  • 11. Effect of FK1052, a potent 5-hydroxytryptamine3 and 5-hydroxytryptamine4 receptor dual antagonist, on colonic function in vivo.
    Kadowaki M, Nagakura Y, Tomoi M, Mori J, Kohsaka M.
    J Pharmacol Exp Ther; 1993 Jul 10; 266(1):74-80. PubMed ID: 8331576
    [Abstract] [Full Text] [Related]

  • 12. A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome.
    Matsueda K, Harasawa S, Hongo M, Hiwatashi N, Sasaki D.
    Scand J Gastroenterol; 2008 Jul 10; 43(10):1202-11. PubMed ID: 18618371
    [Abstract] [Full Text] [Related]

  • 13. Ramosetron Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women.
    Fukudo S, Kinoshita Y, Okumura T, Ida M, Akiho H, Nakashima Y, Nishida A, Haruma K.
    Gastroenterology; 2016 Feb 10; 150(2):358-66.e8. PubMed ID: 26551550
    [Abstract] [Full Text] [Related]

  • 14. Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review and meta-analysis of randomized controlled trials.
    Qi Q, Zhang Y, Chen F, Zuo X, Li Y.
    BMC Gastroenterol; 2018 Jan 08; 18(1):5. PubMed ID: 29310568
    [Abstract] [Full Text] [Related]

  • 15. Optimal dose of ramosetron in female patients with irritable bowel syndrome with diarrhea: A randomized, placebo-controlled phase II study.
    Fukudo S, Matsueda K, Haruma K, Ida M, Hayase H, Akiho H, Nakashima Y, Hongo M.
    Neurogastroenterol Motil; 2017 Jun 08; 29(6):. PubMed ID: 28205278
    [Abstract] [Full Text] [Related]

  • 16. [Pharmacological and clinical profile of ramosetron hydrochloride (Irribow), a novel therapeutic agent for irritable bowel syndrome with diarrhea].
    Hirata T, Funatsu T, Keto Y, Akuzawa S, Akiho H, Nishida A, Sasamata M, Miyata K.
    Nihon Yakurigaku Zasshi; 2009 May 08; 133(5):281-91. PubMed ID: 19443966
    [No Abstract] [Full Text] [Related]

  • 17. Restraint stress stimulates colonic motility via central corticotropin-releasing factor and peripheral 5-HT3 receptors in conscious rats.
    Nakade Y, Fukuda H, Iwa M, Tsukamoto K, Yanagi H, Yamamura T, Mantyh C, Pappas TN, Takahashi T.
    Am J Physiol Gastrointest Liver Physiol; 2007 Apr 08; 292(4):G1037-44. PubMed ID: 17158256
    [Abstract] [Full Text] [Related]

  • 18. Pharmacological evaluation of a novel corticotropin-releasing factor 1 receptor antagonist T-3047928 in stress-induced animal models in a comparison with alosetron.
    Itomi Y, Tanaka T, Matsushita K, Kawamura T, Kojima T, Aso K, Matsumoto-Okano S, Tsukimi Y.
    Neurogastroenterol Motil; 2020 May 08; 32(5):e13795. PubMed ID: 31970891
    [Abstract] [Full Text] [Related]

  • 19. Comparison between partial agonist (ME3412) and antagonist (alosetron) of 5-hydroxytryptamine 3 receptor on gastrointestinal function.
    Kawano K, Mori T, Fu L, Ito T, Niisato T, Yoshida S, Shiokawa S, Sato Y, Murakami H, Shishikura T.
    Neurogastroenterol Motil; 2005 Apr 08; 17(2):290-301. PubMed ID: 15787949
    [Abstract] [Full Text] [Related]

  • 20. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome.
    Andresen V, Camilleri M, Busciglio IA, Grudell A, Burton D, McKinzie S, Foxx-Orenstein A, Kurtz CB, Sharma V, Johnston JM, Currie MG, Zinsmeister AR.
    Gastroenterology; 2007 Sep 08; 133(3):761-8. PubMed ID: 17854590
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.